Partnerships

GlaxoSmithKline Immuno-Oncology Financial Collaboration
Our immuno-oncology financial collaboration with GlaxoSmithKline (GSK) is focused upon the development and commercialization of Anaptys-discovered checkpoint antagonist antibodies to PD-1 and TIM-3. The exclusively licensed products being advanced by GSK under this partnership include Jemperli™ (dostarlimab) and cobolimab in second line NSCLC.
Potential royalties from GSK immuno-oncology financial collaboration

Royalty rate

(annual WW net sales)

(PD-1 antagonist)

8% – $0 to $1 billion

12% – $1.0 to $1.5 billion

20% – $1.5 to $2.5 billion

25% – >$2.5 billion

Cobolimab(TIM-3 antagonist)
  • 4% – $0 to $250 million
  • 5% – $250 to $500 million
  • 6% – $500 to $750 million
  • 7% – $750 to $1.0 billion
  • 8% – >$1.0 billion
  • Royalty rate on cobolimab includes potential cobolimab-portion of combination use with dostarlimab

Remaining retained milestones

(PD-1 antagonist)

  • $75MM when annual net sales ≥ $1 billion
Cobolimab(TIM-3 antagonist)
  • $5MM clinical development
  • $90MM regulatory
  • $165MM commercial

  • Jemperli Capped Non-Recourse Monetization:
  • Selected receivables (designated in orange text above) payable to Sagard until either of the following capped returns achieved:
  • $600MM by March 31, 2031
  • -or-
  • $675MM after March 31, 2031

Note: Anaptys’ capped non-recourse monetization agreement has brought a total of $300 million of non-dilutive capital, including $250 million in Oct. 2021 and $50 million in May 2024.
Note: Sale of Zejula (niraparib) royalty interest in September 2022 to wholly-owned subsidiary of DRI Healthcare Trust for $35mm upfront + $10mm potential milestone upon FDA approval of Zejula for the treatment of endometrial cancer, to the extent that such approval occurs on or before 12/31/25. At present, the Jemperli plus Zejula combination demonstrated significantly improved PFS in primary advanced or recurrent endometrial cancer in the RUBY Phase III trial.
Exclusive Global License Agreement with Vanda Pharmaceuticals for Imsidolimab (IL-36R)

  • Exclusive global license to Vanda

    announced February 2025

  • $15 million upfront payment

    $10 million upfront and $5 million for existing drug supply

  • $35 million future milestones

    $5 million – FDA approval in GPP

    $5 million – EMA approval in GPP

    $25 million – Achievement of $100 million WW annual net sales

  • 10% royalties on global net sales

  • FDA BLA submission for generalized pustular psoriasis (GPP) expected in 2025

Imsidolimab completed two positive global Phase 3 studies in GPP

Vanda plans to expand development into additional indications

Access scientific publications on our immuno-oncology and imsidolimab partnerships.